Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ABVC BioPharma, Inc. (ABVC)
NASDAQ:ABVC
Holding ABVC?
Track your performance easily
ABVC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.41 - $2.45
Previous Close$0.52
Volume100.30K
Average Volume (3M)248.68K
Market Cap
$6.72M
Enterprise Value$7.50M
Total Cash (Recent Filing)$208.15K
Total Debt (Recent Filing)$1.37M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Mar 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding12,975,492
10 Day Avg. Volume672,273
30 Day Avg. Volume248,677
Standard Deviation0.21
R-Squared0.03
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.82
Price to Sales (P/S)13.18
Price to Cash Flow (P/CF)9.80
P/FCF Ratio3.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.20
Enterprise Value/Gross Profit-50.16
Enterprise Value/Ebitda-1.42
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ABVC BioPharma, Inc. News
PremiumCompany Announcements
ABVC BioPharma Releases Corporate Presentation Update
PremiumCompany Announcements
ABVC BioPharma Corrects Licensing Deal FinancialsOwnership Overview
―
Insiders
0.78% Mutual Funds
0.30% Other Institutional Investors
98.56% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ABVC FAQ
What was ABVC BioPharma, Inc.’s price range in the past 12 months?
ABVC BioPharma, Inc. lowest stock price was $0.41 and its highest was $2.45 in the past 12 months.
What is ABVC BioPharma, Inc.’s market cap?
Currently, no data Available
When is ABVC BioPharma, Inc.’s upcoming earnings report date?
ABVC BioPharma, Inc.’s upcoming earnings report date is Mar 28, 2025 which is in 97 days.
How were ABVC BioPharma, Inc.’s earnings last quarter?
ABVC BioPharma, Inc. released its earnings results on Nov 14, 2024. The company reported -$0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.015.
Is ABVC BioPharma, Inc. overvalued?
According to Wall Street analysts ABVC BioPharma, Inc.’s price is currently Overvalued.
Does ABVC BioPharma, Inc. pay dividends?
ABVC BioPharma, Inc. does not currently pay dividends.
What is ABVC BioPharma, Inc.’s EPS estimate?
ABVC BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABVC BioPharma, Inc. have?
ABVC BioPharma, Inc. has 12,975,492 shares outstanding.
What happened to ABVC BioPharma, Inc.’s price movement after its last earnings report?
ABVC BioPharma, Inc. reported an EPS of -$0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.852%.
Which hedge fund is a major shareholder of ABVC BioPharma, Inc.?
Currently, no hedge funds are holding shares in ABVC
---
ABVC BioPharma, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.79%
12-Months-Change
Fundamentals
Return on Equity
-90.91%
Trailing 12-Months
Asset Growth
-16.25%
Trailing 12-Months
Company Description
ABVC BioPharma, Inc.
American BriVision (Holding) Corp. is a clinical stage biopharmaceutical company, which focuses on the development of new drugs and medical devices. The company also integrates research achievements from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. It conducts clinical trials of translational medicine for Proof of Concept and out-licenses it to international pharmaceutical companies. Its products include BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia. The company was founded in 1990 and is headquartered in Fremont, CA.
---
Technical Analysis
---